Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas

Leukemia volume 27, pages 1748–1750 (2013)Cite this article

Subjects

Marginal zone B-cell lymphomas (MZL) are classically characterized by an indolent proliferation of CD5−, CD23−, CD43−, CCND1− and CD10− B cells that strongly express CD19, CD20, CD22, IgM and IgD, even if CD5+ cases have been characterized.1 The World Health Organization (WHO)2 classifies marginal B-cell lymphomas into splenic marginal zone lymphoma (SMZL), nodal MZL and extranodal MZL of mucosa-associated lymphoid tissue (MALT).2 Among the lymphomas developed from the spleen, the splenic diffuse red pulp lymphoma with villous lymphocytes (SDRPLs) has been described as provisional entity close to but distinct from SMZL.2, 3

For small to intermediate-sized circulating abnormal lymphocytes, MZL diagnosis can be of great difficulty, particularly because there is no immunological-positive marker to distinguish MZL from atypical chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and lymphoplasmacytic lymphoma (LPL). Moreover, if translocations involving MALT1 (t(11;18), t(14;18)), BCL10 (t(1;14)) or FOXP1 (t(3;14)) are primarily associated with MALT, and del7q is frequent in SMZL, these cytogenetic markers are not always present. Therefore, there is no specific immunologic marker for splenic or nodal MZL.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Baseggio L, Traverse-Glehen A, Petinataud F, Callet-Bauchu E, Berger F, Ffrench M et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 2010; 95: 604–612.

    Article  CAS  Google Scholar 

  2. Swerdlow SH, Campo E, Harris N, Jaffe ES, Pileri SA, Stein H et al World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, 2008.

    Google Scholar 

  3. Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 2008; 111: 2253–2260.

    Article  CAS  Google Scholar 

  4. Miguet L, Pacaud K, Felden C, Hugel B, Martinez MC, Freyssinet J-M et al. Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. Proteomics 2006; 6: 153–171.

    Article  CAS  Google Scholar 

  5. Miguet L, Béchade G, Fornecker L, Zink E, Felden C, Gervais C et al. Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis. J Proteome Res 2009; 8: 3346–3354.

    Article  CAS  Google Scholar 

  6. Miura Y, Miyake K, Yamashita Y, Shimazu R, Copeland NG, Gilbert DJ et al. Molecular cloning of a human RP105 homologue and chromosomal localization of the mouse and human RP105 genes (Ly64 and LY64). Genomics 1996; 38: 299–304.

    Article  CAS  Google Scholar 

  7. Miura Y, Shimazu R, Miyake K, Akashi S, Ogata H, Yamashita Y et al. RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood 1998; 92: 2815–2822.

    CAS  PubMed  Google Scholar 

  8. Chaplin JW, Kasahara S, Clark EA, Ledbetter JA . Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway. J Immunol 2011; 187: 4199–4209.

    Article  CAS  Google Scholar 

  9. Porakishvili N, Kulikova N, Jewell AP, Youinou PY, Yong K, Nathwani A et al. Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol 2005; 131: 313–319.

    Article  CAS  Google Scholar 

  10. Gutiérrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Fermiñán E et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenström’s macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541–549.

    Article  Google Scholar 

  11. Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012; 209: 1553–1565.

    Article  CAS  Google Scholar 

  12. Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012; 209: 1537–1551.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by research grants from the Institut National du Cancer (INCa PAIR) Lymphome 2008–2011, the Association pour la Recherche en Hématologie Biologique (ARHEB), the Ligue Régionale Contre le Cancer (Comité du Bas-Rhin), the Fondation pour la Recherche Médicale (FRM), the CNRS, the University of Strasbourg UdS, the Région Alsace and the GIS IBiSA. SL was supported by a studentship from the French Ministère de la Recherche. This work is dedicated to the memory of Dr Estelle Zink.

Author information

Author notes

  1. L Miguet, S Lennon and L Fornecker: These authors contributed equally to this work.

Authors and Affiliations

  1. Laboratoire d’Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

    L Miguet, A-C Galoisy, A Eischen, C Mayeur-Rousse, A Maar & L Mauvieux

  2. Laboratoire d’Hématologie cellulaire, EA 3430, Institut d’Hématologie et d’Immunologie, Faculté de Médecine de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France

    L Miguet, N Perrusson & L Mauvieux

  3. Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, IPHC, Strasbourg, France. CNRS, UMR7178, Strasbourg, France

    S Lennon, L Fornecker, A Van Dorsselaer, C Carapito & S Cianférani

  4. Laboratoire d’Hématologie Cellulaire, Centre Hospitalier Lyon-Sud/Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Strasbourg, France

    L Baseggio & P Felman

  5. Service d’Anatomie-pathologique, Centre Hospitalier Lyon-Sud/Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France

    A Traverse-Glehen & F Berger

  6. Service d’Anatomie Pathologique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

    M-P Chenard

  7. Departement d’Oncologie et d’Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

    R Herbrecht

Authors
  1. L Miguet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Lennon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Baseggio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Traverse-Glehen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Perrusson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M-P Chenard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A-C Galoisy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Eischen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Mayeur-Rousse
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Maar
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L Fornecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Herbrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P Felman
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A Van Dorsselaer
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. C Carapito
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. S Cianférani
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. L Mauvieux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Mauvieux.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miguet, L., Lennon, S., Baseggio, L. et al. Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas. Leukemia 27, 1748–1750 (2013). https://doi.org/10.1038/leu.2013.3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.3

This article is cited by

Search

Advanced search

Quick links